Refine by
Clinical Response Services
11 services found
by:Oxitone Medical based inHartford, CONNECTICUT (USA)
Creates Unique Opportunities: Classification of patients into clearly defined diagnostic categories & severities. Predictive trends and multi-parameter baseline variations. Immediate & prolonged clinical response to ...
by:MtoZ Biolabs based in, MASSACHUSETTS (USA)
To accelerate the development of cancer immunotherapy, it is essential to systematically identify tumor antigens that are truly tumor-specific, patient-shared, stably expressed (i. e., cloned) and immunogenic in all malignant cells. Immunopeptidomics is a large-scale and in-depth approach capable of identifying and quantifying the presented human leukocyte antigen (HLA) immunopeptidome. ...
Manufactured by:Creative Biolabs based inShirley, NEW YORK (USA)
Natural autoantibody (NAA) represents a substantial proportion of the normal antibodies, and contributes to the stimulation of primitive innate immune system. Using NAA biomarkers to achieve early diagnosis of infectious disease is promising and can reflect clinical responses to immunotherapy. Empowered by our advanced high-resolution analytical platforms and ...
Manufactured by:Cellworks Research India Private Limited based inBangalore, INDIA
Accelerate drug development timelines, reduce risks and lower costs. Our biosimulation platform predicts human clinical response to investigational drug candidates YEARS earlier than traditional development ...
by:Emergo by UL based inAustin, TEXAS (USA)
Medical device regulations in most countries require foreign manufacturers to appoint an in-country representative. Your representative acts as your liaison to regulatory authorities and assists with device registrations and vigilance/adverse event reporting. It’s important to choose a representative who is familiar with the regulatory requirements for your product to act in the best ...
by:Almac Group based inCraigavon, UNITED KINGDOM
Pharmacodynamic (PD) biomarkers are extremely important in early drug development trials and can be used to measure the level of response to an administered drug, whether it is biologically active & can help to determine target engagement and mechanism of action (MOA). PD Biomarkers assist investigators to understand if the drug is having the intended pharmacologic effect and ...
Manufactured by:Immatics N.V. based inTuebingen, GERMANY
ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ gamma delta T ...
by:ForeSee Medical, Inc. based inSan Diego, CALIFORNIA (USA)
The purpose of a clinical decision support system (CDSS) is to improve healthcare delivery by enhancing medical decisions with focused clinical knowledge, health data, and other patient information. Traditional clinical decision support (CDS) consists of clinical decision support tools designed to aid clinical decision making, in which the conditions of an individual patient are processed against ...
by:Milton Keynes Waste based inMilton, UNITED KINGDOM
Correct management of clinical waste is vital for any healthcare organisation or company. Businesses in the healthcare or medical industry produce large volumes of clinical waste, but our services can cater to many other companies, too. Tattooists, nurseries and nursing homes all produce clinical waste that needs disposing of. If you are looking for a specialist clinical waste disposal service in ...
by:Istari Oncology Inc. based inMorrisville, NORTH CAROLINA (USA)
The tumor environment contains all the ingredients needed to mount an anticancer immune response—tumor antigens, antigen presenting cells (APCs, including tumor-associated macrophages [TAMs] and dendritic cells), and T cells—but activation of the immune system to generate that antitumor response is complex and multifaceted. By “taking the brakes off” the immune response, ...
Manufactured by:Invicro, LLC based inNeedham, MASSACHUSETTS (USA)
Radiopharmaceutical therapies represent an effective way to treat solid cancers by using tumor targeting small molecules, peptides or biologics to deliver a cytotoxic payload that induces DNA damage in tumor cells, while limiting damage to normal and healthy tissue. Streamlined development, evaluation and clinical translation of radiopharmaceuticals requires a partner that has extensive ...